These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 21558488)

  • 1. Telaprevir: an NS3/4A protease inhibitor for the treatment of chronic hepatitis C.
    Smith LS; Nelson M; Naik S; Woten J
    Ann Pharmacother; 2011 May; 45(5):639-48. PubMed ID: 21558488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telaprevir: hope on the horizon, getting closer.
    Weisberg IS; Jacobson IM
    Clin Liver Dis; 2009 Aug; 13(3):441-52. PubMed ID: 19628160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir.
    Suzuki F; Suzuki Y; Akuta N; Sezaki H; Yatsuji H; Arase Y; Hirakawa M; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Iwasaki S; Kumada H
    J Clin Virol; 2010 Jan; 47(1):76-8. PubMed ID: 19857995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VX-950 (Vertex/Mitsubishi).
    Summa V
    Curr Opin Investig Drugs; 2005 Aug; 6(8):831-7. PubMed ID: 16121690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic.
    Thomson JA; Perni RB
    Curr Opin Drug Discov Devel; 2006 Sep; 9(5):606-17. PubMed ID: 17002221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telaprevir: pharmacokinetics and drug interactions.
    Garg V; Kauffman RS; Beaumont M; van Heeswijk RP
    Antivir Ther; 2012; 17(7):1211-21. PubMed ID: 22954756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to anti-HCV protease inhibitors.
    Thompson AJ; Locarnini SA; Beard MR
    Curr Opin Virol; 2011 Dec; 1(6):599-606. PubMed ID: 22440917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Future of antiviral therapy for chronic hepatitis C. Direct antiviral acting medications].
    Lange CM; Sarrazin C; Zeuzem S
    Pharm Unserer Zeit; 2011 Jan; 40(1):60-7. PubMed ID: 21194084
    [No Abstract]   [Full Text] [Related]  

  • 9. Infectious diseases. First specific drugs raise hopes for hepatitis C.
    Enserink M
    Science; 2011 Apr; 332(6026):159-60. PubMed ID: 21474720
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase 3 study results released for telaprevir and HCV.
    AIDS Patient Care STDS; 2010 Oct; 24(10):685-6. PubMed ID: 20945535
    [No Abstract]   [Full Text] [Related]  

  • 11. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.
    Seden K; Back D
    Curr Opin HIV AIDS; 2011 Nov; 6(6):514-26. PubMed ID: 22001895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Journey to the Discovery of Boceprevir: an NS3-NS4 HCV protease inhibitor for the treatment of chronic hepatitis C.
    Chen KX; Njoroge FG
    Prog Med Chem; 2010; 49():1-36. PubMed ID: 20855037
    [No Abstract]   [Full Text] [Related]  

  • 13. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C.
    Moucari R; Forestier N; Larrey D; Guyader D; Couzigou P; Benhamou Y; Voitot H; Vidaud M; Seiwert S; Bradford B; Zeuzem S; Marcellin P
    Gut; 2010 Dec; 59(12):1694-8. PubMed ID: 20861007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus.
    Gentile I; Carleo MA; Borgia F; Castaldo G; Borgia G
    Expert Opin Investig Drugs; 2010 Jan; 19(1):151-9. PubMed ID: 20001560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of the NS3-4A protease inhibitor telaprevir in patients with chronic hepatitis C].
    Ozeki I; Karino Y; Toyota J
    Nihon Rinsho; 2011 May; 69 Suppl 4():267-74. PubMed ID: 22096930
    [No Abstract]   [Full Text] [Related]  

  • 16. Telaprevir-induced DRESS.
    Kesar V; Kesar V; Khaitova V; Motamed D; Schiano T
    J Drugs Dermatol; 2014 Feb; 13(2):199-200. PubMed ID: 24509972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
    López-Labrador FX; Moya A; Gonzàlez-Candelas F
    Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of hepatitis C virus NS3.4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics.
    Perni RB; Chandorkar G; Cottrell KM; Gates CA; Lin C; Lin K; Luong YP; Maxwell JP; Murcko MA; Pitlik J; Rao G; Schairer WC; Van Drie J; Wei Y
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3406-11. PubMed ID: 17482818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interim results presented at EASL from PROVE 1 clinical trial of investigational drug telaprevir in patients with genotype 1 hepatitis C.
    Lang L
    Gastroenterology; 2007 Jun; 132(7):2283-4. PubMed ID: 17570199
    [No Abstract]   [Full Text] [Related]  

  • 20. In vitro and in vivo isotope effects with hepatitis C protease inhibitors: enhanced plasma exposure of deuterated telaprevir versus telaprevir in rats.
    Maltais F; Jung YC; Chen M; Tanoury J; Perni RB; Mani N; Laitinen L; Huang H; Liao S; Gao H; Tsao H; Block E; Ma C; Shawgo RS; Town C; Brummel CL; Howe D; Pazhanisamy S; Raybuck S; Namchuk M; Bennani YL
    J Med Chem; 2009 Dec; 52(24):7993-8001. PubMed ID: 19894743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.